Showing results (1-10 of 12) with videos related to
Sort By:
Pageof 2
Drugs|January 1, 1993
Use of the quinolones in the prophylaxis and treatment of granulocytopenic immunocompromised cancer patientsP Van der Auwera, J GérainDer Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete|February 1, 1992
[Erythema nodosum and AIDS]D Hohl, F Gueissaz, J Gérain, et al.Cytokine|November 1, 1992
High serum levels of TNF-alpha after its administration for isolation perfusion of the limbJ Gérain, D Liénard, P Ewalenko, et al.Cancer Immunology, Immunotherapy : CII|November 1, 1994
Circulating concentrations of interleukin-6 in cancer patients and their pathogenic role in tumor-induced hypercalcemiaB Vanderschueren, J C Dumon, V Oleffe, et al.Circulatory Shock|August 1, 1994
Clinical experience with high-dose tumor necrosis factor alpha in regional therapy of advanced melanomaF Lejeune, D Liénard, A Eggermont, et al.Cellular Immunology|January 1, 1992
Production of tumor necrosis factor-alpha by naive or memory T lymphocytes activated via CD28V von Fliedner, S Miescher, J Gérain, et al.Cytokine|March 7, 1998
Systemic release of soluble TNF receptors after high-dose TNF in isolated limb perfusionJ Gérain, D Liénard, S Pampallona, et al.Annals of Hematology|May 10, 2000
Meropenem versus ceftazidime as empirical monotherapy for febrile neutropenic cancer patientsB Vandercam, J Gérain, Y Humblet, et al.Bulletin Du Cancer|July 1, 1995
[Efficacy of the tumor necrosis factor-alpha (rTNF-alpha) associated with interferon-gamma and chemotherapy in extracorporeal circulation in the limb in inoperable malignant melanoma, soft tissue sarcoma and epidermoid carcinoma. A 4-year experience]F Lejeune, D Liénard, A Eggermont, et al.Journal of Cellular Biochemistry|September 1, 1994
Rationale for using TNF alpha and chemotherapy in regional therapy of melanomaF Lejeune, D Liénard, A Eggermont, et al.Pageof 2